Immunitybio Stock Performance
| IBRX Stock | USD 6.93 0.88 14.55% |
Immunitybio holds a performance score of 22 on a scale of zero to a hundred. The company retains a Market Volatility (i.e., Beta) of 0.63, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, Immunitybio's returns are expected to increase less than the market. However, during the bear market, the loss of holding Immunitybio is expected to be smaller as well. Use Immunitybio maximum drawdown, as well as the relationship between the skewness and day typical price , to analyze future returns on Immunitybio.
Risk-Adjusted Performance
Solid
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Immunitybio are ranked lower than 22 (%) of all global equities and portfolios over the last 90 days. In spite of fairly unfluctuating basic indicators, Immunitybio showed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 14.55 | Five Day Return 10.17 | Year To Date Return 243.07 | Ten Year Return 1.91 | All Time Return (79.99) |
1 | Acquisition by Richard Adcock of 34483 shares of Immunitybio subject to Rule 16b-3 | 01/05/2026 |
2 | ImmunityBio Announces Positive Results Demonstrating ANKTIVA as a Lymphocyte Stimulating Agent in Combination With Checkpoint Inhibitors in Non-Small Cell Lung ... | 01/13/2026 |
3 | Insider Selling ImmunityBio Director Sells 25,000 Shares of Stock | 01/22/2026 |
4 | Stock Market Today, Jan. 23 ImmunityBio Falls After Gaining Over 200 percent in a Month | 01/23/2026 |
5 | ImmunityBio Glioblastoma Data Add Fuel To Rapidly Moving IBRX Story | 01/27/2026 |
6 | ImmunityBio Trading Down 6 percent Heres What Happened | 01/28/2026 |
7 | ImmunityBio Valuation After Convertible Note Amendment And Mixed Clinical And Regulatory Updates | 01/29/2026 |
8 | Piper Sandler See Label Expansion Potential for ImmunityBio, Inc. s ANKTIVA Following QUILT Data | 02/02/2026 |
9 | A Look At ImmunityBio Valuation As ResQ215B Phase 2 Trial Progresses | 02/06/2026 |
10 | ImmunityBios Stock Soars on Promising Trial Results and Strategic Advances - StocksToTrade | 02/09/2026 |
| Begin Period Cash Flow | 265.8 M | |
| Total Cashflows From Investing Activities | -12.2 M |
Immunitybio | Build AI portfolio with Immunitybio Stock |
Immunitybio Relative Risk vs. Return Landscape
If you would invest 206.00 in Immunitybio on November 12, 2025 and sell it today you would earn a total of 487.00 from holding Immunitybio or generate 236.41% return on investment over 90 days. Immunitybio is currently generating 2.351% in daily expected returns and assumes 8.3973% risk (volatility on return distribution) over the 90 days horizon. In different words, 75% of stocks are less volatile than Immunitybio, and 53% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Immunitybio Target Price Odds to finish over Current Price
The tendency of Immunitybio Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 6.93 | 90 days | 6.93 | about 1.81 |
Based on a normal probability distribution, the odds of Immunitybio to move above the current price in 90 days from now is about 1.81 (This Immunitybio probability density function shows the probability of Immunitybio Stock to fall within a particular range of prices over 90 days) .
Immunitybio Price Density |
| Price |
Predictive Modules for Immunitybio
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Immunitybio. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Immunitybio Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Immunitybio is not an exception. The market had few large corrections towards the Immunitybio's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Immunitybio, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Immunitybio within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 2.06 | |
β | Beta against Dow Jones | 0.63 | |
σ | Overall volatility | 1.78 | |
Ir | Information ratio | 0.25 |
Immunitybio Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Immunitybio for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Immunitybio can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Immunitybio is way too risky over 90 days horizon | |
| Immunitybio appears to be risky and price may revert if volatility continues | |
| Immunitybio has high likelihood to experience some financial distress in the next 2 years | |
| Immunitybio currently holds 504.17 M in liabilities. Immunitybio has a current ratio of 0.3, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Immunitybio's use of debt, we should always consider it together with its cash and equity. | |
| The entity reported the previous year's revenue of 14.74 M. Net Loss for the year was (413.64 M) with profit before overhead, payroll, taxes, and interest of 82.18 M. | |
| Immunitybio currently holds about 82.94 M in cash with (391.24 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.21. | |
| Immunitybio has a poor financial position based on the latest SEC disclosures | |
| Roughly 66.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: ImmunityBios Stock Soars on Promising Trial Results and Strategic Advances - StocksToTrade |
Immunitybio Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Immunitybio Stock often depends not only on the future outlook of the current and potential Immunitybio's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Immunitybio's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 700.4 M | |
| Cash And Short Term Investments | 149.8 M |
Immunitybio Fundamentals Growth
Immunitybio Stock prices reflect investors' perceptions of the future prospects and financial health of Immunitybio, and Immunitybio fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Immunitybio Stock performance.
| Return On Asset | -0.37 | ||||
| Operating Margin | (1.74) % | ||||
| Current Valuation | 6.24 B | ||||
| Shares Outstanding | 984.97 M | ||||
| Price To Sales | 72.18 X | ||||
| Revenue | 14.74 M | ||||
| Gross Profit | 82.18 M | ||||
| EBITDA | (264.43 M) | ||||
| Net Income | (413.64 M) | ||||
| Cash And Equivalents | 82.94 M | ||||
| Cash Per Share | 0.21 X | ||||
| Total Debt | 504.17 M | ||||
| Current Ratio | 0.31 X | ||||
| Book Value Per Share | (0.53) X | ||||
| Cash Flow From Operations | (391.24 M) | ||||
| Earnings Per Share | (0.41) X | ||||
| Market Capitalization | 5.96 B | ||||
| Total Asset | 382.93 M | ||||
| Retained Earnings | (3.38 B) | ||||
| Working Capital | 129.64 M | ||||
About Immunitybio Performance
Evaluating Immunitybio's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Immunitybio has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Immunitybio has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.30) | (1.36) | |
| Return On Capital Employed | (1.21) | (1.15) | |
| Return On Assets | (1.24) | (1.30) | |
| Return On Equity | 0.76 | 0.80 |
Things to note about Immunitybio performance evaluation
Checking the ongoing alerts about Immunitybio for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Immunitybio help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Immunitybio is way too risky over 90 days horizon | |
| Immunitybio appears to be risky and price may revert if volatility continues | |
| Immunitybio has high likelihood to experience some financial distress in the next 2 years | |
| Immunitybio currently holds 504.17 M in liabilities. Immunitybio has a current ratio of 0.3, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Immunitybio's use of debt, we should always consider it together with its cash and equity. | |
| The entity reported the previous year's revenue of 14.74 M. Net Loss for the year was (413.64 M) with profit before overhead, payroll, taxes, and interest of 82.18 M. | |
| Immunitybio currently holds about 82.94 M in cash with (391.24 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.21. | |
| Immunitybio has a poor financial position based on the latest SEC disclosures | |
| Roughly 66.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: ImmunityBios Stock Soars on Promising Trial Results and Strategic Advances - StocksToTrade |
- Analyzing Immunitybio's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Immunitybio's stock is overvalued or undervalued compared to its peers.
- Examining Immunitybio's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Immunitybio's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Immunitybio's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Immunitybio's stock. These opinions can provide insight into Immunitybio's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Immunitybio Stock Analysis
When running Immunitybio's price analysis, check to measure Immunitybio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunitybio is operating at the current time. Most of Immunitybio's value examination focuses on studying past and present price action to predict the probability of Immunitybio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunitybio's price. Additionally, you may evaluate how the addition of Immunitybio to your portfolios can decrease your overall portfolio volatility.